Navigation Links
US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
Date:5/26/2011

Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchSunday, June 5, 11:00 AM - 11:15 AM, Arie Crown Theater


  • Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologySunday, June 5, 11:50 AM - 12:10 PM, Hall D2


  • Management of Unique Subsets of Patients with Renal Cell Cancer.Nicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaAlexander Spira, MD, Virginia Cancer SpecialistsSunday, June 5, 12:00 PM - 12:15 PM, Arie Crown Theater


  • Cabozantinib (XL184) has activity in both soft tissue & bone: Results of a phase 2 randomized discontinuation trial (RDT) in patients (pts) w/ advanced solid tumors.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyMonday, June 6, 8:00 AM - 8:15 AM, Hall D2


  • Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.Jeff Sharman, MD, Willamette Valley Cancer Institute and Research CenterDonald Richards, MD, PhD, Texas OncologyMonday, June 6, 9:30 AM - 12:30 PM, Arie Crown Theater


  • Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.Alexander Spira, MD, Virginia Cancer SpecialistsNicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaMonday, June 6, 1:15 PM - 1:30 PM, Hall D1


  • Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.Poster Discussions:Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #23

    Saturday, June 4, 8:
    '/>"/>


  • SOURCE US Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
    3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
    4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
    5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
    6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
    7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
    8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
    9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
    10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
    11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
    (Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
    (Date:8/1/2014)... 2014 MGC Diagnostics Corporation (NasdaqCM: MGCD), ... that it has completed its acquisition of MediSoft ... products based in Sorinnes, Belgium ... cardiorespiratory diagnostics market since 1977. MediSoft, a calendar ... million ($6.3 million) and incurred a net loss ...
    Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4
    (Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ) filed in the wake of the 2012 ... continue to move forward in New Jersey’s Bergen ... to documents filed in the proceeding, the Court ... Order of Confidentiality governing any and all hard ...
    (Date:8/1/2014)... In a first-of-its-kind study, researchers at University Hospitals Rainbow ... infants may be at greater risk for death on ... emergencies on flights worldwide between January 2010 and June ... children under the age of 2. , The ... the rare event of an in-flight pediatric fatality onboard ...
    (Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
    (Date:8/1/2014)... fears, emotions and the benefits of a cancer diagnosis ... according to a study conducted by a researcher at ... to developing an expressive writing intervention is the writing ... facts and events. Writing a journal can be therapeutic, ... determine whether it,s effective or not," said Qian Lu, ...
    (Date:8/1/2014)... August 01, 2014 Market Publishers ... reports have been added to its catalogue. ... Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services ... pharma industry drivers include, among others, increasing ageing ... hygiene. In 2015, the pharma market in India ...
    Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
    ... against blood loss, study finds , , THURSDAY, Sept. 27 ... the rescue of trauma victims suffering from heavy blood ... , "This is the first scientific study showing the ... author Dr. Marie-Pierre Poloujadoff, an emergency physician at one ...
    ... Mich., Sept. 27 Stryker,Corporation (NYSE: SYK ... resolution,with the United States Attorney,s office in Newark, ... practices in the,orthopaedic industry. The investigation began with ... 2005 that requested documents for the,period January 2002 ...
    ... Consumers Measure Their ... Wellness Habits, ... campaign set out to determine if we are a,nation of AlphaWells, ... -- http://www.lifesupplemented.org -- which includes the free,interactive tool My ...
    ... The Patient,Advocate Foundation (PAF) -- a national non-profit ... of patients every year who,are unable to obtain ... --announced this month the addition of four new ... medical professionals ---,Roy Ramthun; Pearl Moore, RN; Alan ...
    ... gene-based screens , , THURSDAY, Sept. 27 (HealthDay News) -- ... genetic tests that predict which patients will have adverse ... nonprofit organization dubbed the International Serious Adverse Events Consortium ... drug-related liver toxicity and the other aimed at a ...
    ... -- Workshops, online programs and databases are just some ... about the biosciences, food safety and animal health with ... food supply. , In the past 27 years, more ... around the world have turned to Kansas State University ...
    Cached Medicine News:Health News:Toxic Shock Drug Might Aid Trauma Victims 2Health News:Toxic Shock Drug Might Aid Trauma Victims 3Health News:Stryker Announces Resolution Related to March 2005 U.S. Department of Justice Subpoena 2Health News:Are You An AlphaWell or An OhWell? 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 3Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 2Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 3Health News:Professionals in bioscience, food-related industries turn to K-State 2Health News:Professionals in bioscience, food-related industries turn to K-State 3
    1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
    0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
    Innovative hemi device combining anatomic design with the advanced material pyrocarbon....
    3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
    Medicine Products: